<\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-07-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-07-02T12:15:21.077Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the cost effectiveness of prescribing medicines for asthma patients; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4130", "label" : {"_value" : "Biography information for Baroness Ritchie of Downpatrick"}
}
, "tablingMemberConstituency" : {"_value" : "South Down"}
, "tablingMemberPrinted" : [{"_value" : "Ms Margaret Ritchie"}
], "uin" : "4661"}
, {"_about" : "http://data.parliament.uk/resources/381490", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/381490/answer", "answerText" : {"_value" : "
There have been no recent discussions between the Secretary of State and the British Medical Association or other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2015-06-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-06-24T11:21:35.273Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what discussions he has had with (a) the British Medical Association and (b) other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "2670"}
, {"_about" : "http://data.parliament.uk/resources/100876", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100876/answer", "answerText" : {"_value" : "
Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.<\/p>
<\/p>
<\/strong><\/p> <\/p>
Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:<\/p>
<\/p>
3.1.1 Adrenoceptor agonists<\/p>
<\/p>
3.1.2 Antimuscarinic bronchodilators<\/p>
<\/p>
3.1.3 Theophylline<\/p>
<\/p>
3.2 Corticosteroids<\/p>
<\/p>
3.3.1 Cromoglicate and related therapy<\/p>
<\/p>
3.3.2 Leukotriene receptor antagonists<\/p>
<\/p>
3.4.2 Allergen immunotherapy (omalizumab only)<\/p>
<\/p>
<\/p>
<\/p>
Cost of drugs for the treatment of asthma, England1<\/sup><\/p><\/td><\/tr>Drug name<\/p><\/td> | Primary Care (£ millions)<\/p><\/td> | Secondary Care (£ millions)<\/p><\/td><\/tr> | 2009<\/p><\/td> | 2010<\/p><\/td> | 2011<\/p><\/td> | 2012<\/p><\/td> | 2013<\/p><\/td> | 2009<\/p><\/td> | 2010<\/p><\/td> | 2011<\/p><\/td> | 2012<\/p><\/td> | 2013<\/p><\/td><\/tr> | Aclidinium Bromide<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 0.02<\/p><\/td> | 1.62<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 0.00<\/p><\/td> | 0.03<\/p><\/td><\/tr> | Aminophylline<\/p><\/td> | 1.25<\/p><\/td> | 1.18<\/p><\/td> | 1.12<\/p><\/td> | 1.08<\/p><\/td> | 1.05<\/p><\/td> | 0.30<\/p><\/td> | 0.29<\/p><\/td> | 0.21<\/p><\/td> | 0.23<\/p><\/td> | 0.22<\/p><\/td><\/tr> | Beclometasone Dipropionate<\/p><\/td> | 84.26<\/p><\/td> | 87.72<\/p><\/td> | 90.30<\/p><\/td> | 97.56<\/p><\/td> | 102.39<\/p><\/td> | 1.62<\/p><\/td> | 1.53<\/p><\/td> | 1.41<\/p><\/td> | 1.49<\/p><\/td> | 1.42<\/p><\/td><\/tr> | Budesonide<\/p><\/td> | 140.35<\/p><\/td> | 149.03<\/p><\/td> | 158.82<\/p><\/td> | 169.14<\/p><\/td> | 177.00<\/p><\/td> | 1.29<\/p><\/td> | 1.14<\/p><\/td> | 1.14<\/p><\/td> | 1.27<\/p><\/td> | 1.41<\/p><\/td><\/tr> | Budesonide/ Formoterol<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 2.75<\/p><\/td> | 2.94<\/p><\/td> | 2.89<\/p><\/td> | 3.10<\/p><\/td> | 3.29<\/p><\/td><\/tr> | Ciclesonide<\/p><\/td> | 0.84<\/p><\/td> | 0.95<\/p><\/td> | 1.03<\/p><\/td> | 1.12<\/p><\/td> | 1.25<\/p><\/td> | 0.01<\/p><\/td> | 0.02<\/p><\/td> | 0.02<\/p><\/td> | 0.02<\/p><\/td> | 0.03<\/p><\/td><\/tr> | Fluticasone<\/p><\/td> | 366.24<\/p><\/td> | 380.56<\/p><\/td> | 387.89<\/p><\/td> | 392.95<\/p><\/td> | 396.10<\/p><\/td> | 1.00<\/p><\/td> | 0.93<\/p><\/td> | 0.91<\/p><\/td> | 1.00<\/p><\/td> | 0.99<\/p><\/td><\/tr> | Fluticasone/ Salmeterol<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 11.46<\/p><\/td> | 11.56<\/p><\/td> | 10.69<\/p><\/td> | 10.82<\/p><\/td> | 10.48<\/p><\/td><\/tr> | Formoterol Fumarate<\/p><\/td> | 5.18<\/p><\/td> | 4.87<\/p><\/td> | 4.68<\/p><\/td> | 4.85<\/p><\/td> | 4.93<\/p><\/td> | 0.10<\/p><\/td> | 0.08<\/p><\/td> | 0.07<\/p><\/td> | 0.06<\/p><\/td> | 0.06<\/p><\/td><\/tr> | Glycopyrronium Bromide<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 0.01<\/p><\/td> | 2.30<\/p><\/td> | 0.58<\/p><\/td> | 0.62<\/p><\/td> | 0.70<\/p><\/td> | 0.79<\/p><\/td> | 1.00<\/p><\/td><\/tr> | Indacaterol Maleate<\/p><\/td> | -<\/p><\/td> | 0.04<\/p><\/td> | 0.30<\/p><\/td> | 0.92<\/p><\/td> | 1.47<\/p><\/td> | -<\/p><\/td> | 0.00<\/p><\/td> | 0.00<\/p><\/td> | 0.02<\/p><\/td> | 0.04<\/p><\/td><\/tr> | Ipratropium Bromide<\/p><\/td> | 16.15<\/p><\/td> | 15.02<\/p><\/td> | 13.74<\/p><\/td> | 10.32<\/p><\/td> | 8.61<\/p><\/td> | 2.74<\/p><\/td> | 2.84<\/p><\/td> | 2.59<\/p><\/td> | 2.65<\/p><\/td> | 2.70<\/p><\/td><\/tr> | Mometasone Furoate<\/p><\/td> | 0.36<\/p><\/td> | 0.31<\/p><\/td> | 0.26<\/p><\/td> | 0.23<\/p><\/td> | 0.21<\/p><\/td> | 0.76<\/p><\/td> | 0.71<\/p><\/td> | 0.61<\/p><\/td> | 0.63<\/p><\/td> | 0.67<\/p><\/td><\/tr> | Montelukast<\/p><\/td> | 38.91<\/p><\/td> | 43.01<\/p><\/td> | 46.96<\/p><\/td> | 51.71<\/p><\/td> | 31.31<\/p><\/td> | 0.98<\/p><\/td> | 1.02<\/p><\/td> | 1.03<\/p><\/td> | 1.16<\/p><\/td> | 0.81<\/p><\/td><\/tr> | Omalizumab<\/p><\/td> | 0.00<\/p><\/td> | 0.01<\/p><\/td> | 0.03<\/p><\/td> | 0.15<\/p><\/td> | 0.12<\/p><\/td> | 5.97<\/p><\/td> | 9.22<\/p><\/td> | 12.16<\/p><\/td> | 14.65<\/p><\/td> | 17.86<\/p><\/td><\/tr> | Salbutamol<\/p><\/td> | 83.15<\/p><\/td> | 82.64<\/p><\/td> | 60.58<\/p><\/td> | 60.37<\/p><\/td> | 59.95<\/p><\/td> | 3.78<\/p><\/td> | 3.77<\/p><\/td> | 3.36<\/p><\/td> | 3.38<\/p><\/td> | 3.29<\/p><\/td><\/tr> | Salmeterol<\/p><\/td> | 48.80<\/p><\/td> | 45.16<\/p><\/td> | 41.87<\/p><\/td> | 36.72<\/p><\/td> | 34.04<\/p><\/td> | 0.87<\/p><\/td> | 0.74<\/p><\/td> | 0.59<\/p><\/td> | 0.53<\/p><\/td> | 0.47<\/p><\/td><\/tr> | Terbutaline Sulphate<\/p><\/td> | 8.61<\/p><\/td> | 8.20<\/p><\/td> | 7.61<\/p><\/td> | 7.43<\/p><\/td> | 7.18<\/p><\/td> | 0.18<\/p><\/td> | 0.16<\/p><\/td> | 0.14<\/p><\/td> | 0.14<\/p><\/td> | 0.15<\/p><\/td><\/tr> | Theophylline<\/p><\/td> | 2.18<\/p><\/td> | 2.17<\/p><\/td> | 2.15<\/p><\/td> | 2.22<\/p><\/td> | 2.26<\/p><\/td> | 0.12<\/p><\/td> | 0.11<\/p><\/td> | 0.11<\/p><\/td> | 0.11<\/p><\/td> | 0.11<\/p><\/td><\/tr> | Tiotropium<\/p><\/td> | 113.61<\/p><\/td> | 129.98<\/p><\/td> | 149.81<\/p><\/td> | 169.35<\/p><\/td> | 185.24<\/p><\/td> | 5.69<\/p><\/td> | 6.03<\/p><\/td> | 6.22<\/p><\/td> | 6.64<\/p><\/td> | 6.87<\/p><\/td><\/tr> | Zafirlukast<\/p><\/td> | 0.79<\/p><\/td> | 0.71<\/p><\/td> | 0.71<\/p><\/td> | 0.70<\/p><\/td> | 0.69<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td><\/tr> | Other drugs2<\/sup><\/p><\/td>0.90<\/p><\/td> | 0.79<\/p><\/td> | 0.66<\/p><\/td> | 0.62<\/p><\/td> | 0.60<\/p><\/td> | 0.04<\/p><\/td> | 0.07<\/p><\/td> | 0.15<\/p><\/td> | 0.26<\/p><\/td> | 0.46<\/p><\/td><\/tr> | Total<\/p><\/td> | 911.6<\/p><\/td> | 952.3<\/p><\/td> | 968.5<\/p><\/td> | 1,007.5<\/p><\/td> | 1,018.3<\/p><\/td> | 40.3<\/p><\/td> | 43.8<\/p><\/td> | 45.0<\/p><\/td> | 49.0<\/p><\/td> | 52.4<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> 1 <\/sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> <\/p> 2<\/sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.<\/p> <\/p> Source:<\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:13:01.0657405Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211846"}
, {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> | <\/td> | 2009-10<\/p><\/td> | 2010-11<\/p><\/td> | 2011-12<\/p><\/td> | 2012-13<\/p><\/td> | 2013-14<\/p><\/td><\/tr> | Asthma<\/p><\/td><\/tr> | Medical Research Council<\/p><\/td> | 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>Other Research Councils and Innovate UK<\/p><\/td> | 0.0<\/p><\/td> | 0.1<\/p><\/td> | 0.3<\/p><\/td> | 1.5<\/p><\/td> | 0.8<\/p><\/td><\/tr> | National Institute for Health Research<\/p><\/td> | 2.6<\/p><\/td> | 3.4<\/p><\/td> | 2.4<\/p><\/td> | 3.4<\/p><\/td> | 3.8<\/p><\/td><\/tr> | Total<\/p><\/td> | 24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>Motor Neurone Research<\/p><\/td><\/tr> | Medical Research Council<\/p><\/td> | 7.0<\/p><\/td> | 7.5<\/p><\/td> | 4.2<\/p><\/td> | 4.1<\/p><\/td> | 3.6<\/p><\/td><\/tr> | Other Research Councils and Innovate UK<\/p><\/td> | 0.2<\/p><\/td> | 0.2<\/p><\/td> | 0.4<\/p><\/td> | 0.7<\/p><\/td> | 1.0<\/p><\/td><\/tr> | National Institute for Health Research<\/p><\/td> | 0.1<\/p><\/td> | 0.1<\/p><\/td> | 0.4<\/p><\/td> | 0.7<\/p><\/td> | 0.5<\/p><\/td><\/tr> | Total<\/p><\/td> | 7.3<\/p><\/td> | 7.8<\/p><\/td> | 5.0<\/p><\/td> | 5.5<\/p><\/td> | 5.1<\/p><\/td><\/tr> | Osteoporosis<\/p><\/td><\/tr> | Medical Research Council<\/p><\/td> | 6.2<\/p><\/td> | 5.4<\/p><\/td> | 5.1<\/p><\/td> | 4.6<\/p><\/td> | 5.9<\/p><\/td><\/tr> | Other Research Councils and Innovate UK<\/p><\/td> | 0.0<\/p><\/td> | 0.0<\/p><\/td> | 0.1<\/p><\/td> | 0.4<\/p><\/td> | 1.0<\/p><\/td><\/tr> | National Institute for Health Research<\/p><\/td> | 0.3<\/p><\/td> | 0.7<\/p><\/td> | 0.8<\/p><\/td> | 1.3<\/p><\/td> | 1.8<\/p><\/td><\/tr> | Total<\/p><\/td> | 6.5<\/p><\/td> | 6.1<\/p><\/td> | 6.0<\/p><\/td> | 6.3<\/p><\/td> | 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211885"}
, {"_about" : "http://data.parliament.uk/resources/58255", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/58255/answer", "answerText" : {"_value" : " The list of medical conditions conferring exemption from prescription charges in England was agreed with the medical profession in 1968. The only addition to the list was the introduction of cancer in 2009. Professor Sir Ian Gilmore, then President of the Royal College of Physicians, was asked in 2008, to consider how this might be extended to cover all those with a long term condition. The Department published his report in May 2010.<\/p> <\/p> In the light of the challenging financial context, the Government made clear in the Spending Review, published in October 2010, that no changes would be made to the current list of medical exemption. Prescription charges in England raise valuable income, in the region of £450 million each year, which helps the National Health Service to maintain vital services for patients.<\/p> <\/p> An extensive system of exemption arrangements, including for those on low incomes who may struggle to pay for their prescriptions, is in place which means that around 90% of all prescription items are already dispensed free of charge. Prescription Prepayment Certificates (PPCs) are also available for those who have to pay NHS prescription charges and need multiple prescriptions. This is the fifth year the cost of an annual certificate, and the third year the cost of a three month certificate, have been frozen. Both certificates will also remain at £104 and £29.10 respectively, next year. There is no limit to the number of items that can be obtained through a PPC. The annual certificate benefits anyone needing more than 12 items a year, and the three month certificate anyone needing more than three items in that three month period.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-06-12", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "199364"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-12T14:36:47.8903664Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if he will abolish prescription charges for asthma medication.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3931", "label" : {"_value" : "Biography information for Dr Julian Huppert"}
}
, "tablingMemberConstituency" : {"_value" : "Cambridge"}
, "tablingMemberPrinted" : [{"_value" : "Dr Julian Huppert"}
], "uin" : "199363"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 7, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|
|
|
|
|
|
|
|
|
|
|
| | |